{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-22-000019","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2022-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.186691+00:00","generated_at":"2026-06-26T04:15:26.174345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q1 revenues up 6% to $6.2B; Non-GAAP EPS $4.25, +15%; reaffirms 2022 guide","bullets":["Total revenues $6.2B (+6% YoY); product sales grew 2% with double-digit volume growth for Repatha, Prolia, EVENITY.","GAAP EPS $2.68 (-5%); Non-GAAP EPS $4.25 (+15%) on revenue growth and lower share count.","GAAP operating income $2.5B (+17%); Non-GAAP operating margin 54.8% (+3.6 ppts).","Free cash flow $2.0B vs $1.9B in Q1 2021.","2022 guidance: revenue $25.4-26.5B; GAAP EPS $12.53-13.58; Non-GAAP EPS $17-18 reaffirmed."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-22-000019","json":"https://secwatch.observer/filing/0000318154-22-000019.json","markdown":"https://secwatch.observer/filing/0000318154-22-000019.md","text":"https://secwatch.observer/filing/0000318154-22-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815422000019/0000318154-22-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815422000019/amgn-20220427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T04:15:26.174345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}